

Press release from Emotra AB (publ)
Göteborg, September 22, 2015

Swedish Patent and Registration Office Approves Emotra's Patent Application

PRV, the Swedish Patent and Registration Office, has notified Emotra of their preliminary approval of Emotra's Swedish patent application, No. 1300614-3, "Apparatus for use in evaluation of suicide risk".

Emotra has been notified that the Swedish Patent and Registration Office intends to approve Emotra's Swedish patent application, No. 1300614-3, "Apparatus for use in evaluation of suicide risk". Emotra's patent application concerns a possible improvement of the existing product by providing greater control of the test situation, which thereby could further improve the method's precision.

Emotra has nevertheless been requested to clear up a handful of minor linguistic imprecisions to clarify the patent text before final approval can be granted. However, this does not affect the PRV's decision to approve Emotra's patent application.

For further information, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se